The Role of Src in Solid Tumors
Open Access
- 1 July 2009
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 14 (7), 667-678
- https://doi.org/10.1634/theoncologist.2009-0009
Abstract
The proto‐oncogene c‐Src (Src) encodes a nonreceptor tyrosine kinase whose expression and activity are correlated with advanced malignancy and poor prognosis in a variety of human cancers. Nine additional enzymes with homology to Src have been identified and collectively are referred to as Src family kinases (SFKs). Together, SFKs represent the largest family of nonreceptor tyrosine kinases and interact directly with receptor tyrosine kinases, G‐protein‐coupled receptors, steroid receptors, signal transducers and activators of transcription, and molecules involved in cell adhesion and migration. These interactions lead to a diverse array of biological functions including proliferation, cell growth, differentiation, cell shape, motility, migration, angiogenesis, and survival. Studies investigating mutational activation of Src in human cancers suggest that this may be a rare event and that wild‐type Src is weakly oncogenic. Thus, the role of Src in the development and progression of human cancer remains unclear. Recently, it was suggested that increased SFK protein levels and, more importantly, SFK tyrosine kinase activity are linked to cancer progression and metastatic disease by facilitating the action of other signaling proteins. This accumulating body of evidence indicates that SFKs may represent a promising therapeutic target for the treatment of solid tumors. This review discusses the role of SFKs in solid tumors and the recent therapeutic advances aimed at targeting this family of tyrosine kinases in cancer.Keywords
Funding Information
- Bristol-Myers Squibb
This publication has 95 references indexed in Scilit:
- Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapyNature Biotechnology, 2008
- Inhibition of Src Family Kinases with Dasatinib Blocks Migration and Invasion of Human Melanoma CellsMolecular Cancer Research, 2008
- Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell linesJournal of Translational Medicine, 2008
- Combined Inhibition of c-Src and Epidermal Growth Factor Receptor Abrogates Growth and Invasion of Head and Neck Squamous Cell CarcinomaClinical Cancer Research, 2008
- Overexpression of c-Src in areas of hyperproliferation in head and neck cancer, premalignant lesions and benign mucosal disordersJournal of Oral Pathology & Medicine, 2007
- Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian CarcinomaCancer Research, 2006
- Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR MutantsPLoS Medicine, 2005
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- Focal adhesion kinase in the brain: novel subcellular localization and specific regulation by Fyn tyrosine kinase in mutant mice.Journal of Bone and Joint Surgery, 1995
- IYK, A Novel Intracellular Protein Tyrosine Kinase Differentially Expressed in the Mouse Mammary Gland and IntestineBiochemical and Biophysical Research Communications, 1995